Alan Leggett

Alan received his Bachelors of Science from the University of Vermont in Biochemistry and Molecular Pharmacology where he completed his thesis on asbestos-induced Malignant Mesothelioma. Upon completion, he worked at The Dana-Farber Cancer Institute in Nathanael Gray’s lab. During this time he focused on the development of small-molecule kinase inhibitors and degraders (PROTACS). He also worked to help develop the ‘dTAG system’ for targeted protein degradation.

Prior to joining hC Bioscience he worked at Skyhawk Therapeutics to develop small molecules that modify RNA expression.